| References: |
Molidustat, also known as BAY 85-3934, is a novel inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells. Phase I data have shown that inhibition of HIF-PH by Molidustat results in an increase in endogenous production of EPO. Molidustat is currently clinical trials at Bayer for the treatment of patients suffering from renal anemia due to chronic kidney disease. For the detailed information of Molidustat(BAY 85-3934), the solubility of Molidustat(BAY 85-3934) in water, the solubility of Molidustat(BAY 85-3934) in DMSO, the solubility of Molidustat(BAY 85-3934) in PBS buffer, the animal experiment (test) of Molidustat(BAY 85-3934), the cell expriment (test) of Molidustat(BAY 85-3934), the in vivo, in vitro and clinical trial test of Molidustat(BAY 85-3934), the EC50, IC50,and affinity,of Molidustat(BAY 85-3934), For the detailed information of Molidustat(BAY 85-3934), the solubility of Molidustat(BAY 85-3934) in water, the solubility of Molidustat(BAY 85-3934) in DMSO, the solubility of Molidustat(BAY 85-3934) in PBS buffer, the animal experiment (test) of Molidustat(BAY 85-3934), the cell expriment (test) of Molidustat(BAY 85-3934), the in vivo, in vitro and clinical trial test of Molidustat(BAY 85-3934), the EC50, IC50,and affinity,of Molidustat(BAY 85-3934), Please contact DC Chemicals. |
